Health 2.0 announces keynotes and preliminary program

11 - 12 May 2016, Barcelona, Spain.
Health 2.0 announces keynote speakers and preliminary program for the 7th Annual Health 2.0 Europe Conference. After a highly successful conference last May in Barcelona, the International event series will be back for another 3 full days discussing challenges faced by the healthcare system and showcasing the latest technologies and innovations that are making an impact.

Health 2.0 Europe is a truly international conference, bringing speakers from all across the world to discuss and find solutions to those healthcare challenges from a global perspective. It will bring together 600 digital health champions including entrepreneurs, executives, thoughtleaders, investors, physicians, and patients over insightful keynotes, interactive workshops, animated round tables and more than 50 rapid fire live demo.

The keynote speakers already confirmed are:

  • Esther Dyson, active business angel and board member in various healthcare companies, she was named by Forbes as one of the most powerful American business woman. She will share her vision on the healthcare challenges and how to tackle them.
  • Dr. Rafael Grossmann, the surgeon who practiced the 1 st live surgery using Google Glass will showcase exclusive innovative solutions he is using and that are supporting both healthcare professionals and enhancing patients' experience.
  • Damien Marmion, Global Head of Health at AXA, will share AXA’s vision as an insurance pioneer in reimbursing digital health solutions and the role of reimbursement in accelerating adoption of digital health in Europe.
  • Dr. Julio Mayol, chief medical and innovation officer at San Carlos Hospital in Madrid, will give his vision on how hospitals should look at health 2.0 solutions and present their successful Smart Health Lab, an initiative launched to design, develop and implement innovative solutions.
  • Pēteris Zilgalvis, Head of Unit for eHealth and Well Being in DG CONNECT, will share the vision and strategic plan of the European Commission on getting a more dynamic digital health ecosystem, involving every stakeholder.

Health 2.0 Europe takes into account all the different stakeholders of the digital health ecosystem. Some of the topics that we will be discussing this year:

  • Solutions for hospitals and healthcare professionals
  • Building a new framework for Health 2.0 adoption in the clinic setting
  • Building Blocks to a Dynamic Health 2.0 Ecosystem in Europe
  • Health 2.0 Applications in Emerging Markets
  • Data Analytics: Structuring Information for DecisionMaking
  • Choosing your Digital Health Accelerator
  • Pharma 2.0: Going Beyond the Pill
  • Frontiers of Health 2.0: What's Next?
  • Power to the patient
  • Technology promoting behaviour change and healthy
  • Health 2.0 transforming the daily mission of nurses
  • Who will pay for Health 2.0? An investor's discussion
  • Reimbursement players, trends, criteria and processes
  • SHUSH topics and the famous unmentionables
  • From Health to WellBeing: the rise of wearables and consumer interfaces

For further information and to register, please visit:
https://goo.gl/IVCb3P

Early bird prices end on 18th March. Book you ticket now using the code EHNEWS16 to get 15% discount.

About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to our flagship event held in the Bay Area each Fall, we host events around the world including in Europe, Latin America and India, and new for 2015 Korea and Japan.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...